Author + information
- Chen Jingrui,
- Xiaoxue Xing,
- Hui Gao and
- Guanwei Fan
The present study was aimed to explore the effects and mechanisms of QSYQ on ischemia-reperfusion injury rats, which include cardiac dysfunction, disorders in myocardial structure and hemodynamic, with particularly focusing on platelets aggregation.
Sprague-Dawley rats were pre-treated with QSYQ, or saline for 7 days, and were subjected to ischemia (30 min occlusion of the left anterior descending coronary artery) and followed by 2 h reperfusion. Cardiac functions were evaluated by echocardiogram and hemodynamics were evaluated by left ventricular catheterization, immediately after 2 h after reperfusion. Myocardial histology was assessed through HE staining. Thromboxane B2 (TXB2), 6-keto-prostaglandin F1α (6-Keto-PGF1α), platelet factor 4 (PF4), E-selectin, β-platelet globulin (β-TG), fibrinogen(FIB) and cyclic adenosine monophosphate (cAMP) contents in the plasma were detected by Enzyme-Linked Immunosorbent Assay.
Echocardiography showed left ventricular ejection fraction (EF) and fractional shortening (FS) decreased significantly in saline group (EF: 41.46±3.26, FS: 20.72±1.79), QSYQ can significantly increase the EF and FS of the I/R injured rats (EF: 59.73±3.91, FS: 29.66±1.20). In addition, compared with saline group, QSYQ significantly increase the LVSP (saline group vs QSYQ group: 89.40±4.44 vs 95.75 ±4.62), and ±dp/dt max (saline group vs QSYQ group: 4234.84±392.60 vs 5374.28±419.84; -3911.16±165.95 vs -4284.72±299.40) of the I/R injure rats; HE staining results also showed that QSYQ can reduce myocardial inflammatory infiltration of I/R injure rats and protect myocardial tissue. Moreover, the level of plasma TXB2 (15.14±2.21), PF4 (1928.12±166.72), E-selectin (35.22±3.57), β-TG (42.32±6.64) and FIB (2120.27±312.89) increased in saline group, compared to Sham group. Pretreatment with QSYQ attenuated I/R-induced increase in TXB2, PF4, E-selectin, β-TG and FIB (10.58±0.54, 606.23±126.20, 23.64±4.69, 27.39±6.68 and 1660.98±208.15 respectively). The plasma 6-Keto-PGF1α (0.75±0.03), cAMP (33.05±8.13) and the ratio of 6-Keto-PGF1α/TXB2 (60.85±19.23) in saline group was lower than that in the sham group, all of which were significantly ameliorated by pre-treatment with QSYQ (0.91±0.10, 47.62±1.14 and 85.65±15.25 respectively P<0.05). These results suggest that Qishenyiqi pills can suppress ischemia-reperfusion injury induced platelet aggregation in rats with I/R injury, inhibit the inflammatory response and improve cardiac function.
The results of the present study suggest that QSYQ protects against myocardial I/R injury via antiplatelet aggregation and activation action. Further, we provided evidence to speculate that the regulation of cAMP level, prostaglandins synthesis, 6KFG/TXB2 and TXB2 synthesis may be involved in the therapeutic action of QSYQ.